265 related articles for article (PubMed ID: 21486216)
1. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.
Montagner IM; Merlo A; Zuccolotto G; Renier D; Campisi M; Pasut G; Zanovello P; Rosato A
PLoS One; 2014; 9(11):e112240. PubMed ID: 25383653
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin.
Hribaschek A; Pross M; Kuhn R; Krüger S; Ridwelski K; Halangk W; Boltze C; Lippert H
Anticancer Drugs; 2002 Jul; 13(6):605-14. PubMed ID: 12172506
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.
Li PC; Chen LD; Zheng F; Li Y
J Cancer Res Clin Oncol; 2008 Jan; 134(1):37-44. PubMed ID: 17665213
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis.
Luo J; Wu Z; Lu Y; Xiong K; Wen Q; Zhao L; Wang B; Gui Y; Fu S
Int J Biol Macromol; 2020 Jun; 152():718-726. PubMed ID: 32126201
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
Hribaschek A; Kuhn R; Pross M; Meyer F; Fahlke J; Ridwelski K; Boltze C; Lippert H
Surg Today; 2006; 36(1):57-62. PubMed ID: 16378195
[TBL] [Abstract][Full Text] [Related]
8. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2011 Jan; 12(2):1009-29. PubMed ID: 21541039
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
[TBL] [Abstract][Full Text] [Related]
10. [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Hribaschek A; Pross M; Ridwelski K; Meyer F; Fenske A; Krüger S; Lippert H
Zentralbl Chir; 2004 Aug; 129(4):328-34. PubMed ID: 15354258
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
De Stefano I; Battaglia A; Zannoni GF; Prisco MG; Fattorossi A; Travaglia D; Baroni S; Renier D; Scambia G; Ferlini C; Gallo D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):107-16. PubMed ID: 20848284
[TBL] [Abstract][Full Text] [Related]
12. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
Yu J; Lee HJ; Hur K; Kwak MK; Han TS; Kim WH; Song SC; Yanagihara K; Yang HK
Invest New Drugs; 2012 Feb; 30(1):1-7. PubMed ID: 20669041
[TBL] [Abstract][Full Text] [Related]
13. Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice.
Dai M; Xu X; Song J; Fu S; Gou M; Luo F; Qian Z
Cancer Lett; 2011 Dec; 312(2):189-96. PubMed ID: 21943824
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Fujita K; Kubota Y; Ishida H; Sasaki Y
World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
17. Camptothecine encapsulated composite drug delivery system for colorectal peritoneal carcinomatosis therapy: biodegradable microsphere in thermosensitive hydrogel.
Liu L; Wu Q; Ma X; Xiong D; Gong C; Qian Z; Zhao X; Wei Y
Colloids Surf B Biointerfaces; 2013 Jun; 106():93-101. PubMed ID: 23434697
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
19. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
20. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
England RM; Hare JI; Barnes J; Wilson J; Smith A; Strittmatter N; Kemmitt PD; Waring MJ; Barry ST; Alexander C; Ashford MB
J Control Release; 2017 Feb; 247():73-85. PubMed ID: 28043863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
